Cardiologist, Cardiology department, Cardio VID clinic, Universidad de Antioquia, Medellín, Colombia.
Cardiologist, Cardiology department, Fundación Valle de Lili, Cali, Colombia.
Curr Probl Cardiol. 2022 Oct;47(10):101301. doi: 10.1016/j.cpcardiol.2022.101301. Epub 2022 Jun 24.
We aimed to describe and compare characteristics and outcomes of patients with a worsening heart failure episode included in the RECOLFACA registry during 2017-2019 vs population from VICTORIA trial. 2528 patients were included, 1890 (74.8%) had an ejection fraction <45% and a worsening episode. VICTORIA population was similar to RECOLFACA patients in mean age (67.3 vs 66.9 years), ejection fraction (28.9% vs 28.4%), the prevalence of COPD (17.1% vs 15.7%), and the median eGFR (61.5 vs 61.4 mL/min/1.73m2). RECOLFACA patients were mostly women, with a lower prevalence of atrial fibrillation, diabetes mellitus, and coronary artery disease. The 1-year heart failure hospitalization rate was 29.6% in the placebo group of VICTORIA, compared to 26.9% in RECOLFACA. Patients enrolled in the RECOLFACA that met the VICTORIA definition had more similar characteristics and outcomes compared to the VICTORIA population. There is an opportunity to improve this unmet need with the use of vericiguat.
我们旨在描述和比较 2017-2019 年 RECOLFACA 登记研究中纳入的射血分数降低的心力衰竭恶化患者的特征和结局，并与 VICTORIA 试验人群进行比较。共纳入 2528 例患者，其中 1890 例（74.8%）射血分数<45%，且出现心力衰竭恶化。VICTORIA 人群与 RECOLFACA 患者的平均年龄（67.3 岁 vs 66.9 岁）、射血分数（28.9% vs 28.4%）、COPD 患病率（17.1% vs 15.7%）和中位 eGFR（61.5 vs 61.4 mL/min/1.73m2）相似。RECOLFACA 患者以女性为主，心房颤动、糖尿病和冠状动脉疾病的患病率较低。VICTORIA 安慰剂组 1 年心力衰竭住院率为 29.6%，而 RECOLFACA 组为 26.9%。RECOLFACA 中符合 VICTORIA 定义的患者与 VICTORIA 人群相比，具有更相似的特征和结局。使用维立西呱有可能改善这一未满足的需求。
